Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, +28

The Lancet Oncology

Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical Trials +8

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

Stefan Schönland, Ute Hegenbart, Tilmann Bochtler, +5

Blood

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

Tilmann Bochtler, Ute Hegenbart, Christina Kunz, +9

Journal of Clinical Oncology

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Krämer, Tilmann Bochtler, Chantal Pauli, +12

Annals of Oncology

Esophageal CancerUnknown PrimaryMedicineCancer ManagementPathology +4

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Anna Brown, Peer Arts, Catherine Carmichael, +56

Blood Advances

Allelic VariantDevelopmental BiologySomatic MutationsSomatic VariantEpigenetic Regulation +13

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis

Tobias Dittrich, Tilmann Bochtler, Christoph Kimmich, +6

Blood

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Anuhar Chaturvedi, Lena Herbst, Stefan Pusch, +25

Leukemia

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaPan-mutant-idh1 Inhibitor Bay1436032Cancer Genetics +6

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

Tilmann Bochtler, Ute Hegenbart, Friedrich W. Cremer, +9

Blood

Karyotype complexity and prognosis in acute myeloid leukemia

Friedrich Stölzel, Brigitte Mohr, Michael Krämer, +23

Blood Cancer Journal

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

Tilmann Bochtler, Ute Hegenbart, Christina Kunz, +10

Amyloid

Hematological MalignancyPrognostic EvaluationAlzheimer's DiseaseOncologyPlasma Cells +12